×
Search
[custom_company_search_form]
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)
Iron Ore
100.85
2.03%
Lithium
41.58
0.2%
Gold
2,617.80
(0.69%)
Copper
4.09
(0.92%)
Oil
71.29
1.24%
Bitcoin
93,594.42
0.04%
USD/AUD
0.62
0.1%
FTSE 100
8,121.01
(0.35%)
Nikkei 225
39,894.54
(1.07%)
Dow Jones
42,689.83
(0.41%)
Hang Seng
20,041.42
(0.41%)

Clarity Pharmaceuticals Ltd

CU6

ASX

Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company provides innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

Latest Posts

Line Chart with Gradient
Price
$4.240
-0.01 (-0.24%)
At Close 27/12 (AEST)
Related Companies
RECCE PHARMACEUTICALS LTD
$RCE
ANAGENICS LIMITED
$AN1
MELODIOL GLOBAL HEALTH LIMITED
$ME1DE
IMMUTEP LIMITED
$IMM
LTR PHARMA LIMITED
$LTP

Leave a Comment on CU6


Comments for CU6

    Latest Posts

    clarity-pharmaceuticals-asx-cu6-announces-new-prostate-cancer-trial-cu6
    Health Care $CU6
    Clarity Pharmaceuticals (ASX: $CU6) announces new prostate cancer trialInitiates Co-PSMA trial to compare 64Cu-SAR-bisPSMA with 68Ga-PSMA-11 for prostate cancer detection
    November 18, 2024
    clarity-pharmaceuticals-asx-cu6-develops-next-generation-radiopharmaceuticals-for-cancer-treatment-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) develops next-generation radiopharmaceuticals for cancer treatment

    Global leader in Targeted Copper Theranostics with significant supply and logistical benefits

    September 18, 2024
    clarity-pharmaceuticals-asx-cu6-advances-secure-trial-with-strong-preliminary-efficacy-data-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) advances secure trial with strong preliminary efficacy data

    Cohort 4 shows positive safety profile and significant PSA reduction in prostate cancer patients

    September 12, 2024
    clarity-pharmaceuticals-asx-cu6-signs-supply-agreement-with-terrapower-for-ac-225-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) signs supply agreement with TerraPower for ac-225

    Agreement to develop best-in-class TAT 225Ac-bisPSMA product with secure supply

    July 16, 2024
    clarity-pharmaceuticals-asx-cu6-completes-retail-entitlement-offer-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) completes retail entitlement offer

    Raises approximately $10.8 million in final stage of capital raising

    April 24, 2024
    clarity-pharmaceuticals-asx-cu6-announces-equity-raising-to-fund-clinical-programs-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) announces equity raising to fund clinical programs

    A$121m raised to strengthen balance sheet and advance clinical portfolio

    April 4, 2024
    clarity-pharmaceuticals-asx-cu6-completes-placement-and-institutional-entitlement-offer-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) completes placement and institutional entitlement offer

    Raises $110 million to advance clinical portfolio and strengthen balance sheet

    March 28, 2024
    clarity-pharmaceuticals-asx-cu6-raises-a121m-to-fund-clinical-programs-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) raises A$121m to fund clinical programs

    Developing next-generation radiopharmaceuticals for cancer treatment

    March 26, 2024
    clarity-pharmaceuticals-asx-cu6-launches-121-million-equity-raising-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) launches $121 million equity raising

    Underwritten equity raising to fund clinical program and product development

    March 26, 2024
    clarity-pharmaceuticals-asx-cu6-treats-first-participant-in-final-secure-trial-cohort-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) treats first participant in final SECURE trial cohort

    Phase I/II SECURE trial progresses to final dose escalation phase with 67Cu-SAR-bisPSMA

    March 22, 2024
    clarity-pharmaceuticals-asx-cu6-advances-theranostic-prostate-cancer-trial-to-multi-dose-phase-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) advances theranostic prostate cancer trial to multi-dose phase

    SECURE trial progresses to cohort 4 with favorable safety profile and promising PSA reductions

    March 15, 2024
    clarity-pharmaceuticals-asx-cu6-reveals-enhanced-detection-of-prostate-cancer-lesions-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX: $CU6) reveals enhanced detection of prostate cancer lesions

    64Cu-SAR-bisPSMA detects lesions as small as 2mm, potentially revolutionizing prostate cancer diagnosis

    March 6, 2024
    clarity-pharmaceuticals-asxcu6-closes-recruitment-early-for-diagnostic-phase-ii-trial-cu6
    Health Care $CU6

    Clarity Pharmaceuticals (ASX:CU6) closes recruitment early for diagnostic phase II trial

    Phase II trial for 4CU-SARTATE in neuroendocrine tumours concludes with early recruitment closure

    December 19, 2023
    clarity-pharmaceuticals-asx-cu6-highlights-strategic-advancements-at-annual-meeting-cu6
    Health Care $CU6
    Clarity Pharmaceuticals (ASX: $CU6) highlights strategic advancements at annual meetingCompany discusses SAR Technology, clinical trials, and executive expansion at fourth Annual General Meeting

    November 20, 2024

    clarity-pharmaceuticals-asx-cu6-outlines-clinical-and-strategic-advancements-cu6
    Health Care $CU6
    Clarity Pharmaceuticals (ASX: $CU6) outlines clinical and strategic advancementsCompany progresses oncology trials and expands manufacturing capabilities for copper radioisotope therapies.

    November 20, 2024

    CU6

    $CU6

    Clarity Pharmaceuticals (ASX: $CU6) advances theranostic prostate cancer trial to multi-dose phase

    SECURE trial progresses to cohort 4 with favorable safety profile and promising PSA reductions

    CU6

    $CU6

    Clarity Pharmaceuticals (ASX: $CU6) reveals enhanced detection of prostate cancer lesions

    64Cu-SAR-bisPSMA detects lesions as small as 2mm, potentially revolutionizing prostate cancer diagnosis

    CU6

    $CU6

    Clarity Pharmaceuticals (ASX:CU6) closes recruitment early for diagnostic phase II trial

    Phase II trial for 4CU-SARTATE in neuroendocrine tumours concludes with early recruitment closure

    Load More
    No More Posts
    Related Companies
    NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
    $NSB
    IMMURON LIMITED
    $IMC
    ALGORAE PHARMACEUTICALS LIMITED
    $1AI
    AVECHO BIOTECHNOLOGY LIMITED
    $AVE
    EPSILON HEALTHCARE LIMITED
    $EPN

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions